OKYO Pharma to Present Urcosimod Phase 2 Study Results at ASCRS Annual Meeting

OKYO Pharma's lead candidate, urcosimod, has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. The presentation will highlight efficacy and safety data from a proof-of-concept Phase 2 study in patients with neuropathic corneal pain. The study showed positive efficacy signals, including meaningful pain reduction and encouraging corneal nerve health trends. A larger Phase 2b/3 trial is planned for the first half of 2026.